Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 202

1.

Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End.

Casado JL.

AIDS Rev. 2016 Apr-Jun;18(2):59-68. Review.

PMID:
27230467
2.

Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.

Casado JL, Del Rey JM, Bañón S, Santiuste C, Rodriguez M, Moreno A, Perez-Elías MJ, Liaño F, Moreno S.

J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):416-22. doi: 10.1097/QAI.0000000000000986.

PMID:
26962850
3.

Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.

Estrada V, Monge S, Gómez-Garre MD, Sobrino P, Masiá M, Berenguer J, Portilla J, Viladés C, Martínez E, Blanco JR; CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network.

HIV Med. 2016 Oct;17(9):653-61. doi: 10.1111/hiv.12368. Epub 2016 Mar 3.

PMID:
26935006
4.

Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013.

Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V; Cohorte de la Red de Investigación en Sida, Spain.

J Infect. 2016 May;72(5):587-96. doi: 10.1016/j.jinf.2016.01.017. Epub 2016 Feb 24.

5.

Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.

Casado JL, Santiuste C, Vazquez M, Bañón S, Rosillo M, Gomez A, Perez-Elías MJ, Caballero C, Rey JM, Moreno S.

AIDS. 2016 Jun 1;30(9):1423-31. doi: 10.1097/QAD.0000000000001067.

PMID:
26919733
6.

Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy.

Sainz-de-la-Maza S, Casado JL, Pérez-Elías MJ, Moreno A, Quereda C, Moreno S, Corral I.

Eur J Neurol. 2016 May;23(5):919-25. doi: 10.1111/ene.12963. Epub 2016 Feb 23.

PMID:
26914970
7.

Development and Validation of an HIV Risk Exposure and Indicator Conditions Questionnaire to Support Targeted HIV Screening.

Elías MJ, Gómez-Ayerbe C, Elías PP, Muriel A, de Santiago AD, Martinez-Colubi M, Moreno A, Santos C, Polo L, Barea R, Robledillo G, Uranga A, Espín AC, Quereda C, Dronda F, Casado JL, Moreno S.

Medicine (Baltimore). 2016 Feb;95(5):e2612. doi: 10.1097/MD.0000000000002612.

8.

Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.

Casado JL, Bañón S, Santiuste C, Serna J, Guzman P, Tenorio M, Liaño F, del Rey JM.

AIDS. 2016 Jan;30(2):231-9. doi: 10.1097/QAD.0000000000000901.

PMID:
26684820
9.

Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.

Casado JL, Bañón S.

Expert Rev Clin Pharmacol. 2015;8(6):709-18. doi: 10.1586/17512433.2015.1090873. Review.

PMID:
26517111
10.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

11.

Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance.

Abad-Fernández M, Dronda F, Moreno A, Casado JL, Pérez-Elías MJ, Quereda C, Moreno S, Vallejo A.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):286-90. doi: 10.1097/QAI.0000000000000608.

PMID:
26181704
12.

The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.

Casado JL, Marín A, Romero V, Bañón S, Moreno A, Perez-Elías MJ, Moreno S, Rodriguez-Sagrado MA.

HIV Med. 2016 Jan;17(1):46-55. doi: 10.1111/hiv.12280. Epub 2015 Jul 6.

PMID:
26149493
13.

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.

Casado JL, Mena A, Bañón S, Castro A, Quereda C, Moreno A, Pedreira J, Moreno S.

HIV Med. 2016 Jan;17(1):62-7. doi: 10.1111/hiv.12274. Epub 2015 Jun 30.

PMID:
26122981
14.

Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response.

Casado JL, Esteban MA, Bañón S, Moreno A, Perez-Elías MJ, Mateos ML, Moreno S, Quereda C.

Dig Dis Sci. 2015 Nov;60(11):3473-81. doi: 10.1007/s10620-015-3773-y. Epub 2015 Jun 26.

PMID:
26112991
15.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group.

Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Erratum in: Lancet Infect Dis. 2015 Aug;15(8):875.

PMID:
26062880
16.

Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).

Expert Panel of GESIDA and the National AIDS Plan, Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Estrada V, García F, Gatell JM, González-García J, Gutiérrez F, Iribarren JA, Knobel H, Llibre JM, Locutura J, López JC, Miró JM, Moreno S, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz-Moreno J, Sanz J, Téllez MJ, Tuset M, Rivero A.

Enferm Infecc Microbiol Clin. 2015 Oct;33(8):544-56. doi: 10.1016/j.eimc.2015.03.017. Epub 2015 May 26.

PMID:
26021186
17.

[GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].

Panel de expertos de GeSIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2015 Oct;33(8):543.e1-43. doi: 10.1016/j.eimc.2015.03.016. Epub 2015 May 7. Spanish.

PMID:
25959461
18.

Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy.

Casado JL, Machuca I, Bañón S, Moreno A, Moltó J, Rodriguez MA.

Antivir Ther. 2015;20(7):773-7. doi: 10.3851/IMP2961. Epub 2015 Apr 16.

PMID:
25879675
19.

Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.

Casado JL, Abad-Fernández M, Moreno S, Pérez-Elías MJ, Moreno A, Bernardino JI, Vallejo A.

HIV Med. 2015 Apr;16(4):240-8. doi: 10.1111/hiv.12206. Epub 2015 Jan 21.

20.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

Supplemental Content

Loading ...
Support Center